In Thursday’s Wall Street session, Moderna Inc (NASDAQ:MRNA) shares traded at $26.93, up 3.38% from the previous session.
MRNA stock price is now -0.84% away from the 50-day moving average and -39.45% away from the 200-day moving average. The market capitalization of the company currently stands at $10.41B.
With the price target of $40, Citigroup recently initiated with Neutral rating for Moderna Inc (NASDAQ: MRNA). On February 18, 2025, Barclays Downgraded its previous ‘Overweight’ rating to ‘Equal Weight’ on the stock reducing its target price from $111 to quote $45, while ‘Goldman’ rates the stock as ‘Neutral’
In other news, Bancel Stephane, Chief Executive Officer bought 160,314 shares of the company’s stock on Mar 03 ’25. The stock was bought for $5,004,318 at an average price of $31.22. Upon completion of the transaction, the Chief Executive Officer now directly owns 9,210,686 shares in the company, valued at $248.04 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Mar 03 ’25, Director SAGAN PAUL bought 31,620 shares of the business’s stock. A total of $1,004,251 was incurred on buying the stock at an average price of $31.76. This leaves the insider owning 312,027 shares of the company worth $8.4 million. A total of 11.44% of the company’s stock is owned by insiders.
During the past 12 months, Moderna Inc has had a low of $23.15 and a high of $158.82. As of last week, the company has a debt-to-equity ratio of 0.07, a current ratio of 4.22, and a quick ratio of 4.14.
The net profit margin was -105.67% and return on equity was -29.34% for MRNA. The company reported revenue of $108.0 million for the quarter, compared to $167.0 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -35.33 percent.
